Diadema Partners »

Ultragenyx Pharmaceutical shares owned by Diadema Partners

Quarter-by-quarter ownership of Ultragenyx Pharmaceutical (RARE) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Ultragenyx Pharmaceutical

Tip: Access up to 7 years of quarterly data

All positions including Ultragenyx Pharmaceutical held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ultragenyx Pharmaceutical by Diadema Partners

Quarter filed Position value Share count Share price at filing
2025-09-30 $8.5M 283k 30.08

More positions owned by Diadema Partners

Jazz Pharmaceuticals Shs Usd (JAZZ)
Soleno Therapeutics (SLNO)
Uniqure Nv SHS Put Option (QURE)
Regeneron Pharmaceuticals (REGN)
Viking Therapeutics (VKTX)
Bristol Myers Squibb (BMY)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
BioMarin Pharmaceutical (BMRN)
Avidity Biosciences Ord (RNA)
Agios Pharmaceuticals Call Option (AGIO)
Ultragenyx Pharmaceutical (RARE)
Incyte Corporation Call Option (INCY)
Intellia Therapeutics Call Option (NTLA)
Vaxcyte (PCVX)
Eli Lilly & Co. Put Option (LLY)

View all positions for Diadema Partners

Top funds holding Ultragenyx Pharmaceutical

Vanguard Group
FMR
BlackRock
Jpmorgan Chase & Co
Sands Capital Management
State Street Corporation
Rtw Investments
Baker Bros. Advisors
Jacobs Levy Equity Management
Suvretta Capital Management
Wellington Management Company
Geode Capital Management
Deutsche Bank Aktiengesellschaft
Bnp Paribas Investment Partners
Standard Life Aberdeen

View all funds holding Ultragenyx Pharmaceutical